SFM
BCAX

Soros Fund Management’s Bicara Therapeutics BCAX Stock Holding History

Soros Fund Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-20,000
Closed -$509K – 253
2024
Q3 		$509K Buy
+20,000
New +$510K 0.01% 170

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Soros Fund Management's BCAX Position: Q4 2024 in Review

Soros Fund Management sold out of Bicara Therapeutics (BCAX) in Q4 2024, closing a stake of 20,000 shares — an estimated $509K sold.

Soros Fund Management first reported a position in BCAX in Q3 2024 and held it in 1 quarter. The position peaked at $509K in Q3 2024. 84 funds tracked by Wall St. Rank hold BCAX as of Q4 2024.

  • Soros Fund Management reported no remaining Bicara Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Soros Fund Management sold 20,000 Bicara Therapeutics shares in Q4 2024, an estimated $509K.
  • Soros Fund Management first reported a position in Bicara Therapeutics in Q3 2024 and held it in 1 quarter.
  • Soros Fund Management's Bicara Therapeutics position peaked at $509K in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q4 2024.

Based on Soros Fund Management's 13F filing for Q4 2024, filed 14 Feb 2025.